Loading…
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $206M | $-6M | $-16M | $1M | -24.3% | 14.3% | -25.3% |
| 2024 | $180M | $-10M | $-21M | $9M | -37.3% | 15.3% | -44.2% |
| 2023 | $156M | $-26M | $-37M | $-48M | -71.2% | -3.5% | -12.4% |
| 2022 | $162M | $-34M | $-43M | $-28M | -63.3% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 162.05 | 156.37 | 180.27 | 206.13 |
| Operating Revenue | - | 162.05 | 156.37 | 180.27 | 206.13 |
| Cost Of Revenue | - | 74.95 | 69.97 | 80.75 | 93.84 |
| Gross Profit | - | 87.09 | 86.40 | 99.52 | 112.29 |
| Operating Expense | - | 121.18 | 112.72 | 113.75 | 120.97 |
| Research And Development | - | 64.11 | 67.64 | 58.91 | 67.72 |
| Selling General And Administration | - | 83.34 | 75.52 | 75.89 | 80.91 |
| Total Expenses | - | 196.13 | 182.69 | 194.50 | 214.81 |
| Operating Income | - | -34.08 | -26.32 | -14.22 | -8.68 |
| Total Operating Income As Reported | - | -34.08 | -30.05 | -14.22 | -8.68 |
| EBITDA | - | -33.52 | -26.34 | -10.02 | -5.51 |
| Normalized EBITDA | - | -32.83 | -21.96 | -10.39 | -4.24 |
| EBIT | - | -36.51 | -28.94 | -11.88 | -6.94 |
| Interest Expense | - | 5.83 | 8.39 | 8.88 | 8.34 |
| Net Interest Income | - | -5.83 | -8.39 | -8.88 | -8.34 |
| Other Non Operating Income Expenses | - | -1.74 | 1.76 | 1.98 | 3.02 |
| Other Income Expense | - | -2.42 | -2.61 | 2.35 | 1.74 |
| Interest Expense Non Operating | - | 5.83 | 8.39 | 8.88 | 8.34 |
| Net Non Operating Interest Income Expense | - | -5.83 | -8.39 | -8.88 | -8.34 |
| Pretax Income | - | -42.34 | -37.32 | -20.76 | -15.28 |
| Tax Provision | - | 0.49 | 0.32 | 0.20 | 0.35 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -0.14 | -0.92 | 0.08 | -0.27 |
| Net Income Continuous Operations | - | -42.82 | -37.65 | -20.96 | -15.64 |
| Net Income From Continuing And Discontinued Operation | - | -42.78 | -37.49 | -20.92 | -15.63 |
| Net Income From Continuing Operation Net Minority Interest | - | -42.78 | -37.49 | -20.92 | -15.63 |
| Net Income | - | -42.78 | -37.49 | -20.92 | -15.63 |
| Net Income Common Stockholders | - | -42.78 | -37.49 | -20.92 | -15.63 |
| Net Income Including Noncontrolling Interests | - | -42.82 | -37.65 | -20.96 | -15.64 |
| Normalized Income | - | -42.23 | -34.03 | -21.21 | -14.62 |
| Diluted NI Availto Com Stockholders | - | -42.78 | -37.49 | -20.92 | -15.63 |
| Basic Average Shares | - | 176.54 | 180.27 | 184.56 | 190.59 |
| Diluted Average Shares | - | 176.54 | 180.27 | 184.56 | 190.59 |
| Reconciled Depreciation | - | 2.98 | 2.60 | 1.86 | 1.43 |
| Reconciled Cost Of Revenue | - | 74.95 | 69.97 | 80.75 | 93.84 |
| Total Unusual Items | - | -0.69 | -4.38 | 0.37 | -1.27 |
| Total Unusual Items Excluding Goodwill | - | -0.69 | -4.38 | 0.37 | -1.27 |
| Minority Interests | - | 0.05 | 0.16 | 0.04 | 0.01 |
| Special Income Charges | - | 0 | -3.73 | 0 | 0 |
| Restructuring And Mergern Acquisition | - | 0 | 3.73 | 0 | 0 |
| Gain On Sale Of Security | - | -0.69 | -0.65 | 0.37 | -1.27 |
| Other Operating Expenses | - | -26.27 | -30.43 | -21.05 | -27.66 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Cerus Corporationthis co. | CERS | $559M | - | 8.70 | -24.3% | - |
| Altimmune, Inc. | ALT | $568M | -6.45 | 2.53 | -39.2% | -6.43 |
| Tactile Systems Technology, Inc. | TCMD | $568M | 29.74 | 2.59 | 8.7% | 12.42 |
| MiMedx Group, Inc. | MDXG | $563M | 11.59 | 2.19 | 18.9% | 5.27 |
| Rigel Pharmaceuticals, Inc. | RIGL | $560M | 1.52 |
| - |
| - |
| - |
| - |
| - |
| 1.43 |
| 93.8% |
| 4.35 |
| Ironwood Pharmaceuticals, Inc. | IRWD | $560M | 23.30 | -2.14 | -9.2% | 9.00 |
| Cytek Biosciences, Inc. | CTKB | $559M | -8.40 | 1.64 | -19.5% | -28.29 |
| NeuroPace, Inc. | NPCE | $556M | -25.92 | 29.24 | -112.8% | -50.21 |
| Fulgent Genetics, Inc. | FLGT | $554M | -9.15 | 0.50 | -5.4% | -11.16 |
| Peer Median | - | -2.46 | 1.92 | -7.3% | -1.04 | |